<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECT: Vascular endothelial growth factor (VEGF) is a secreted <z:chebi fb="0" ids="52290">mitogen</z:chebi> associated with <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>The conceptual basis for therapeutic <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> after plasmid human VEGF gene (phVEGF) transfer has been established in patients presenting with limb <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The authors hypothesized that overexpression of VEGF using a gene transfer method combined with indirect vasoreconstruction might induce effective brain <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>, leading to prevention of ischemic attacks </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> model induced by permanent ligation of both common carotid arteries in rats was used in this investigation </plain></SENT>
<SENT sid="4" pm="."><plain>Seven days after induction of <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>, encephalomyosynangiosis (EMS) and phVEGF administration in the temporal muscle were performed </plain></SENT>
<SENT sid="5" pm="."><plain>Fourteen days after treatment, the VEGF gene therapy group displayed numbers and areas of capillary vessels in temporal muscles that were 2.2 and 2.5 times greater, respectively, in comparison with the control group </plain></SENT>
<SENT sid="6" pm="."><plain>In the brain, the number and area of capillary vessels in the group treated with the VEGF gene were 1.5 and 1.8 times greater, respectively, relative to the control group </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: In rat models of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>, administration of phVEGF combined with indirect vasoreconstructive surgery significantly increased capillary density in the brain </plain></SENT>
<SENT sid="8" pm="."><plain>The authors' results indicate that administration of phVEGF may be an effective therapy in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>, such as those with <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya disease</z:e> </plain></SENT>
</text></document>